Neurotoxicity of antineoplastic drugs.
D006585:Altretamine / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects; D001921:Brain / Q000187:drug effects / Q000528:radiation effects; D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000517:prevention & control; D002945:Cisplatin / Q000009:adverse effects; D003391:Cranial Nerves / Q000187:drug effects; D006801:Humans; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D008727:Methotrexate / Q000009:adverse effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011344:Procarbazine / Q000009:adverse effects; D012306:Risk; D014057:Tomography, X-Ray Computed; D014748:Vinca Alkaloids / Q000009:adverse effects
D000970:Antineoplastic Agents; D014748:Vinca Alkaloids; D011344:Procarbazine; D001215:Asparaginase; D002945:Cisplatin; D006585:Altretamine; D008727:Methotrexate